前苏联专利SU1551246A3 Method of producing phthalizineacetic acids or their pharmaceutically acceptable additive salts

专利PDF首页>>前苏联专利

专利附录

专利说明

权利要求

类似技术

同族专利

引用文献

法律状态

优先权

专利摘要:
A heterocyclic oxophthalazinyl acetic acid having aldose reductase inhibitory activity has the formula <CHEM> wherein X is oxygen or sulfur, Z is a covalent bond, O, S, NH or CH2; R1 is hydroxy, or a prodrug group; R2 is a heterocyclic group, R3 and R4 are hydrogen or the same or a different substituent, and R5 is hydrogen or methyl. The pharmaceutically acceptable acid addition salts of the above compounds wherein R1 is di(C1-C4)alkylamino or (C1-C4)alkoxy substituted by N-morpholino or di(C1-C4)alkylamino and the pharmaceutically active base addition salts of the above compounds wherein R1 is hydroxy are also aldose reductase inhibitors.
公开号:SU1551246A3
申请号:SU864028554
申请日:1986-11-06
公开日:1990-03-15
发明作者:Лакшамана Милари Банавара；Роберт Ларсон Эрик；Джеймс Зембровски Вилльям
申请人:Пфайзер Инк (Фирма)；
IPC主号:

专利说明:

ten
Table 3
8, CHzCOaR
.one
8.8 8.9 8..1
8.12 8.13
8.14 8.15
5-CH,
4-F, 5-F 5-C1, 6-C1
5-C1, 7-C1 4-C1, 5-C1
4-C1, 7-C1 6-0C3
NMR (CDC1 ,, 60 MHz):
3.6 (s, 3N), 4.0 (s, 2H);
5.7 (s, 2H); 7, 2H) /, 6 (m, 5H), 8.4 (m, H)
119-120
I18-120
I13-116
152-155
160-161
V NMR (COC13, 60 MGi): 1.2 (g, Hz, ZR) -, 4, l (s, 2H) i 4.2 (Hz, 2K), 5.8 (s, 2K) 7.8 (m, 2H), 7.8 (m, 4H); 8.4 (m, W).
134-136
121-122
(H NMR (SPS13 "90 MHz): 3.70 (s.ZN); 4.0 (s, 2H), 5.75 (s, 2H); 7.6-8.0 (m, 5H) j 8.3-8.6 m, 1H)
144-145
1F NMR (CDC13, 90 MHz): I, 20 (T., Hz, 3N); 4.00 (s, 2H), (q, Hz, 2F) j 5.80 (s, 2H), 7.40 (d, L Hz, 1H); 7.60 (d, J Hz, 1H), 7.6-7.9 (m, 3N); 8.4-8.6 (m, 1H).
C2P5173
CH, fH NMR (CDC13, 90 MHz) G
3.70 (s, SG); 3.8 (s.ZN), 4.05 (s, 2H), 5.75 (s, 2F);
CzEf CrE5 CF,
C2Hf
CHj

5-CH; 6-CH,
SI
8.18
6-Ieopropil
8.19
5 -F
8.205-CH3
8.21
6,7-leH to 5 -F
8.22
6.7 Beiso
8.23
5-C1
8.24
7-C1
8.25
C1
i l. 3
AND
,
2.5
7.00 (dd, 9 Hz, IF); 7.20 (d, Hz, NO, 7.67 .9 (m, 4H), 8.4-8.6 (m, 1H).
123-124
F NMR (CDC1, 90 MHz): 2.50 (s.N); 3.75 (s, 3N);
4.10 (s, 2H); 5.90 (s, 2H); 7.35 (fl, J 8 Guy, 1H); 7.65-8.10 (m, 4H); 8.5-8.7
1N MP (CDC13, 90 MHz): 8.40 (m, IF), 7.9-7.5 (m, 5F); -, 2 (d, IH);
5.79 (s, 2H), 4.15 (q, g, 2H); 3.85 (s, 2H); 2.98 (cen.J 9 Hz, 1H); 1.28 (d, Hz, 6F); 1.20 (5, Hz, 3F).
H NMR (CDCl1, 90 MHz): I, 20 (t, Hz.ZN); 4.00 (s, 21); 4.20 (KB, Hz2H),
5.80 (s, 2H); 7.2-8.1 (m, 7H) H NMR (CDC13, 90 MHz): 1.20 (t, L 8 Gp, 3N); 2.95 (s, 3N), 3.95 (s, 2H), 4.20 (sq. L
8 gi, 2H); 5.75 (s, 2H), 7.2-8.1 (h, 7H). 1H NMR CDC13, 90 MHz): I, 20 (t, J 8 Hz, ЗН), 3.95 (s, IF), 4.20 (q, J - 8 Hz, 2H) j 5.90 (s, 2H); 7.25-8.00 (m, 8H), 8.80 (dd, J 3.7 Hz, 1H). And YAUR (CDC1 ,, 90 MHz): I, 20 (t., L 8 Hz, ZN); 2.95 (s, 3N), 3.95 (s, 2H); 4.15 (q, L 8 Hz, 2F); 5.90 (s, 2H); 7.4-7.95 (m, 8H), 8.80 (m, 1H). H NMR (SPSG, 90 MHz): 1.20 (t, L 8 Hz, 3N); 4.05 (s, 2H) 4.25 (q.L 8 Hz, 2H), 5.85 (s, 2H) {7.2-8.1 (m, 6H), 8.50 (d, L 2 Hz, 1H) H NMR (CDC13, 90 MHz): 1.25 (t, L 8 Hz, 3N); 4.00 (s, 2H), 4.20 (q, L 8 Hz, 2H); 5.80 (s, 2H); 7.25-7.6 (m, 2H); 7.65- 7.90 (m.ZN), 8.00 (dz, L 2.9 Hz, 1H) J 8.45 (d, J 9 Hz, 1H) H NMR (CDC1, 90 MHz): 1 , 20 (t, l 8 Hz, ZN); 4.00 (s, 2H); 4.20 (q.L 8 Hz, 2H); 5.80 (s, 2H); 7.2-7.6 (m, 2H), 7.78 .1 (m, 3N) - 8.55 (s, 1H)
8.26
6 -Br
Cfh5
8.27
6 -NO,
cn5
8.28
6-isop icnitii .29
6 --OCH
C ,, F,
8.30
6 -CF
C2P5
8.:and
7s
san5
8.32
cn5
8.:i3
7 - Isopropyl
CrH5
8.347 -OCCH3
Continued table.1
four
H NMR (CDCl1, 90 MHz) -1.20 (t, j = 8 Hz, 3N); 3.90 (s, 2H) 4.15 (KB, J 8 Ge, 2H); 5.80 (s, 2H), 7.2-8.1 (M, 6H) j 8.60 (d, J- 2 Hz, 1H) H NMR (SOSTS, 90 MGy): 20 (i, J 8 Hz, 3N), 4.05 (s, 2H) 4.20 (KB, J 8 Hz, 2H); 5.80 (s, 2H); 7.2-7.6 (m, 2H), 7.7 (m, 3N); 8.60 (dd, L 2.9 Hz, 9.30 d, J 3 Hz, IH)
H NMR (CDCL ,, 90 MHz): 8.25 (cJH), 7.9 (m, IF); 7, / (m 3N); 7.3 (m, 2H), 5.8 (s, 2NCh, 4 (kb, J 9 Gu, 2H) 3.95 (s, 2H)
3, (sep. J- 9 Hz, 1H); , 35 (d, J 9 Hz, 6H); 1, 20 (s, J 9 Guy, ZN)
H NMR (CDCl1, 90 MHz): 1.20 (t, J = 8 Gy, 3N); 3.95 (br, g, 6H); 4.15 (KB, J 8 Hz, 2P) 5.30 (s, 2H), 7.20-8.10 (m, 7H). 1F NMR (CDC13, 90 MHz): 8.7 (s, I). 8, 15-7.7 (m, 4H), 7.40 (, m, 2b),, 8 (); 4.21 (q. T 9 Hz, 2H) 1 4.0 (s, 2H), 1.22 (5SJ 9 Hz, 3N) {H NMR (CDflj 90 MHz): 1.20 (g,: 8 Gu) , ЗН) -, 3.90 (с, 2Н
4.15 (KB, J 8 Hz, 2n), 5.85 (s, 2H); 7.15-7.50 (m, 2H), 7.6 8.1 (m, 4H); 8.30 (d, J 9 Gu) B NMR (CDC13, 90 MHz): 1.20 (g, J - 8 Hz, GD) -, 2.60 (s.N). 4.15 (s, 2P) i 4.20 (KB, J 8 Gui 2U-, 5.80 (s, 2H), 7.3-8.2 (m, bUa, 8.30 (d, J 0 Hz, 1H).
1H NMR (CDC13, 300 MHz): 8.24 (d, J 9 Hz, IF); 7.84 (ff, j h Hz, 1H); 7, b2 (d, J - 9 Hz, 1H); 7.49 (d, J = 9 Hz, 1H); t, j6 (s, H) | 7.26 (t, J 6 Hz IF), 7.16 (r, J 6 Hz, 1H); 5.64 (s, 2H); 4.06 (q, L 9 Hz, 1H); 1.30 (d, J 9 Hz. 6H), 1.17 (t, J 9 Hz, ZN) H NMR (CDC13, 90 MHz): 1.20 (T, J - 8 Hz, ZN) -, 3 , 85 (s, ZN); 3.90 (s, 2H); 4.20 (KB, J 8 Hz 2F); 5.80 (s, 2H); 7.00 (dL 2 Hz, IF), 7.2-7.5 (m, 3N); 7.75 (dd, J - 2.8 Hz, H); 8.00 (ds, J 1, 7 Hz, 1H); 8.50 (d, J 9 Hz, 1H)
8.36
7 -NO,
CZH5
8.37
6.7 -Benzo 7 -C1
C2H5
5-CF,
s, n5
Replace-I Product Characteristics
R | Replace- | Character Jf jtel 1 m.pl.
NMR)
Example 9. To a mixture of ethyl 4-oxo-3H-phthalazin-1-ylacetate (23.4 g) in dimethylformamide (175 ml), the temperature of which is maintained at 10 ° C, potassium tert-butoxide (11.2 d). portions of 5 minutes The temperature of the resulting orange solution is brought to room temperature and 5-trifluoromethyl-2-chloromethylbenzothiazole in dimethylformamide (25 ml) is added over 15 minutes. Conv / Table:. j
(d, J 9 Hz, IH) i 8.15-7.70 (m, 4H); , 2 (m, 2H), 5.7 (s, 2H); 4.2 (KB, J 9 Hz, 2H) 4.05 (s, 2H); 1.18 (t, J 9 Hz, ZN)
H NMR (CDC1 ,, 90 MHz): 1, 20 (t, J - 8 Hz, 3N); 4.05 (s, 2H), 4.20 (KB, J 9 Hz, 3N); 5.80 (s, 2H); 7.2-7.6 (m, 3N); 7.6-8.1 (m, 2H); 8.4-8.7 (m, 2H) 1H NMR (CDC1 ,, 90 MHz):, 20 (t, J 8 Gu / NN); 4.00 (s, 2H), 4.20 (cl, J 8 Hz, 2H); 5.90 (s, 2H); 7.5-8.0 (m, 7P); 8.45 (d, J 9 Gt :, 1H), 8.75-8.90 (m, N)
134-136
T a b l and c a 4
CH2C02C-iH5
NMR)
1.2 (t, J 9 Hz, 3N); 3.85. (s, 2H), 4.2 (9, J 9 Hz, 2H); 6.0 (s, 2H); 7.1-8.0 (m, 7H)) 8.2-8.4 (m, 1H)
The mixture was hardly stirred for 30 minutes. The mixture was poured into ice-cold water (1500 ml). The solid precipitate is collected and the mixture is washed with isopropyl alcohol - hexane (250/500). The yellow solid is air dried to give 44.32 ethyl 3- (5- trifluoromethyl-2-benzothiazolylmethyl) -4-oxo phthalazinylacetate, mp. 134-136 ° C.
СН2С02.ггЦ 7 6
C, OO
HsJ-N / 4
O1
enzothiazolyl
aestitel rl
5-C1 - 5-Вг 5-С1,7-С1
596 Venzo
Product
Not selected Not selected Not selected Mass spectra m / s main peak 431.06 (partially highlighted)
mp.167-17E ° С
According to the method of winner 6, compounds are obtained from the above compounds without isolating them (see table 5)
2-F, 6-Cl-Phenyl
12
11.3
2-Pyridyl 2-Br ™ «be Nile
Benzyl
2-F-phenyl
3-C1,4-C1-ennl
Example 1 1. According to the method of 1
measure 3B, the compounds are prepared, shown in Table 6.
T a b l i and a b
H NMR (CDC1, 60 MHz): 1.3 (T, J 8 Gg, 3N); 4.0 (s, 2H); 4.2 (KB, J 8 Gu, 2H); 5.8 (s, 2H); 7.3 (m, 3N), 7.8 (m, 3N); 8., 4 (m, 1K).
118-123
(H 5SR (CDC1 ,, 60 MHz): 1.3 (t, J 8 Hz, 3N); 4.0 (s, 2F) -, 4.2 (KB, J 8 Hz, 2H); 5.7 (s, 2H); 7.2 (m, 2H); 7.8 (m, 4H), 8.4 (m, IP) 76-80
100-105
138-140
Example 12. According to the method of the example of ES, the compounds shown in Table 7 are obtained.
Table 7
Example i S. 3 - IAAO In-L-i;, -methyl) 4-oxo-3H-6, 7-dichloro 6 talan
R1
-1 - iluacetic acid (, X - O,
HE; R2 quinolin-2-yl; Rj R4 - Cl).
A.4, 5-Dichloro Phthalic anhydride. A mixture of 1 l, 5-dichloro phthalic acid
(50.4 g) and acetic anhydride (50 ml is refluxed for 2 hours. After cooling, the precipitated product is collected and dried under vacuum (37.0 g, mp. ISO-)
B.3-Ethoxycarbonylmethylidene-5,6-dichlorophthalide.
A solution of 4,5-dichloro phthalic anhydride (10.0 g) and carboxymethylenetriphenylphosphorane (16.0 g) in chloroform (450 ml) is heated under reflux for 6 hours. After evaporation of the chloroform and treatment of the residue on a chromatographic a silica gel column gives 9.34 g of product.
C. Ethyl-6,7-dkchlor-4-oxo-3H-phta-lasin-1-ylacetate.
A mixture of 3-ethoxycarbonylmethylidene-5,6-dichloroftalide (9537 g), ethanol (300 ml) and hydrazine (1.1 ml) was heated under reflux for 3 hours. After cooling, the precipitated

ten
15
20
25
,,
thirty
1 35
40
.

ml) and
iBf-rydy product comp .ngg (6.85:, mass spectrum m / s 300 and 227).
D. The title compound is obtained from ethnl-gt, 7-dichloro-4-oxo-zp-phthala zin-1 and 2-hcrmetnlquinoline as described in Example 6, mp. 202-203 ° C.
Example 14. 3- (Quinolin-2-ylmethyl) -4-oxo-ZN-phthalazin-1-acetic acid (I, 1 X - O, R, - OH; R3r.R4-H; K2-chi: 1O l in 2 Il),
To a solution of ethyl 4-oxo-3H-Phthalasia-1-ethyl acetate (1.0 g) and sodium hydrate (60% w / w dispersing mineral oil) in dnmethylformamide (30 ml) is added 2 -bromomethylquinoling (1, 05 g), Obtained: p, 1ST orop is stirred at room temperature P for 30 min, poured into ox (100 ml) containing cn „FC1 (5 ml) and extrudate ethyl acetate. The organic extract is premyra-gt water (ml), dried and evaporated to give ethl-3 - (quinolin-2-ylm) t-oxo-phthalazin-1-ylacetate (1.54 g). This substance is dissolved in a water dioxap mixture (70 ml / 70 ml). To this plant is added 5 n. Kagich hydroxide (5 mt). obtained-nnmy solution stirring r pi; : .o iHpij; the fori temperature was 5 N-IN, the dioxac was removed, diluted with water (150 ml) was not extracted with ethylagidate (ml), the pH of the aqueous layer KOSH1SNS1 was adjusted to 2. The precipitated precipitate was carefully grown. Hot Eg acetate, and then filtered to obtain the indicated compound (0.54 g, mp 193-194 ° C).
G p and measures 15. According to the method of Example 6, the compounds listed in Table 8 are obtained.
Spreadsheets
but
g
50
55
-2,2,4-skadadiazol-3-yl
2: 11551246
Prg zolom1e tabl.Ya
15.33 - Fenshshzs Tiazod-5- 169-170-yl
55.43 Phenylisotism Eop-4 2 8
-ip
15.52 - Phenyl - 1, 3,4-o-260 diazol-b il
5.6 4,5-DiFenschukeaeol- 197-200
-2-yl 5.7 Quinolin-2-yl 193-194
15.8Hinoxan-2 or 21 5-2 7
15.9N- Methylbenzimchdz- 230 sol-2-yl (decomp.)
15.10Oxazolo 4,5 bPI - 228-230 din-2-yl.
15.11Tiazolo 5.4-bb-216
qing-2-yl
15.125,7-Dichlorhikolin-- 200-20 2-yl
15.13b-Bromhinopin - 2-sh (
15.146,8-Dkhlorhknolyn-193-I95 -2-yl
15.153-Methyl-1,2,5-ti-160-I62 adiazol-4-yl
r-007Pi
OH
6
R.
Benlyzothiazol-3-gp SP,
3-Fb Nilisothiaeol -5
-il
3-F
-il
3-Phenylneothiazole- +
2-Phenyl-1 ,, 3, 4-OKG i-diazol-5-yl
24
Continuation of table.8

5-Phenyloxazol-2-yl
594 Feiiloxazol - 2-yl1812-Fznlthiazol-5-yl 6 i2-o-fluoroPhenylthia-i84 aol-5-yl
4 Phenyltkazol-2-1Y5-Chlorobenzothiophene-20S- -2-yl
7-Chlorimvdazo / 19 | 1, 5 - and Pyndic-2-yy
3-ChlorobenzotisPhen-13
Imidazolpirvdzhni, with
Chlorcmidazolpiri-:
din
3- (2,4-diFluoroFekyl) -1, 2, 4-oxadiazol-5-yl
and measure 16. According to the method, Grig compounds are produced in Thai.
i R 165 1b5
ISA 201
22G
T a b l and c 9
Characteristics of the product CMD, so pl., ° C)
i1 NMR (CDCljt GO MHz): 3, (s, Vrl); 4-0 (s, 2H), 5.8 (s, 2H). 7.6 (m, 7H); 8.3 (m. 1H 98-104
H NMR (CDC1 ,, 60 MHz): 1.2 (t, J 8 Hz, 3N); 3.9 (s, 2H); 4.2 (KB, J 8 Hz, 2H) i 5.4 (s, 2H); 7.5 (m, 7H); 8.4 (m, 1H); 8.8 (s, H) fll NMR (CDC15, 60 MHz): 1.2 (t, J 3 Hz, 3N) - 4.0 (s, 2H); 4.2 (-sn, J 8 Hz, 2H) j 5.7 (s, 2H), 7.4 (m, 3N); 7.8 (m, 5H) 1 8.4 (m, 1H)
5- (2-Chlorosyl) -1,2,4-oxadiazol-3-yl
N-ketilbenzimidazol-2-yl
g i
Oxazolo 4, 5-cj pi
din-2-il
Thiazole 5.4 with pyridine-2-l
5-Phenylox ol-2-yl 4-Phenycloazol-2-yl 2-Phenylthiazol-5-yl 2-o-Fluoro-3enthia-aol-5-yl
4-Phenyltnazol-2-yl Z-Chlorbenzo iofen-2-yl
Example 17, CK-MirFolino (5, 6-diUloro-benzothiazol-2-yl-methyl) -4 oxo-ZP-Ftalazn-1-yl iethat, hydrochloride.
To the sodium salt of N-2-hydroxyethylmorphine obtained by carefully adding sodium hydride (0.45 g, 50% w / w disperse mineral oil) to a solution of N-2-hydroxyethylmorpholine (1.43 ml) , in toluene (50 ml), a solution of ethylbenzothiazole 2-ylmethyl-4-oxo-5,6-dichloro phthalazine-ethyl acetate (1.23 g) in toluene (30 ml) is added. After stirring the reaction mixture at room temperature for 24 hours and then at 60 ° C for 6 hours, it is treated with gaseous HC1 and the precipitated solid is added to a saturated solution of sodium bicarbonate (100 ml) and extracted with ethyl acetate (ml) . The organic layer was dried and evaporated, and the remaining solid was dissolved in acetone (30 ml). Treatment of this solution with FC1 gas results in the preparation of a compound (0.12 g, which is characterized according to elemental analysis data — C 49.83%, H 3.83%, N 9.36%).
Continuation of tes.9
H1-F (CDCL ,, 60 UHz L l, 3 (r, J - 8 Hz, 3II) S 4.0 (s, 211); 4.2 (k, J 8 Hz, 2F); 5.6 (s , 2H), 7.4 (g :, ZN) -, 1. B (m, 4H), 8.4 (m, 1H).
05-107
115-117 130-131 1 04-106 104-107
120-124 139-142
thirty
Example 18, Sodium-3- (5-cpc-gormetilbenzotna aeol-2-nlmethyl) a cco-e H -it t h lz in-ylacelt.
five
0
five
0
five
At room temperature, 54 mg of sodium mystic is added to 3- (5-β-trifluoromethylbenzothisol-2-ylmetl) -4-oxofine-lasin-1-yl-acetic acid (0.4 g) in methanol (10 ml) and the resulting clear solution stir the pepper for 1 to 5 minutes at room temperature. The excess methanol is evaporated. The residue was triturated with shlrom (20 ml) and filtered to obtain the product (C, 43 g, mp 300 ° C).
Example 19. 3- (5-Tris-3-tshtbenzothiazol-2-ylmethyl) -4-oxo-3N-β-phthalazin-1-ylai-ietat, dicyclohexn-amino salt.
- To a mixture of 3- (5-trifluoromethylbenzothiazol-2-ylmethyl) -4-oxo-phthalazin-1-yl-acetic acid (0.42 g) in methanol (10 ml), dicyclo-hexyl (0.2 g) in methanol is added (5 ml). The resulting solution:, rh; gb solution is stirred at KOMi i 1 or temperature for 15 minutes, and then evaporated to dryness. As a result of careful trituration of the residue with ether (30 ml), a white solid is obtained (0.38 g, mp; 207 ° C) /
I
Note p 20, i 5-Three /; op ™ methylbenzothiazsl-2 nlm t; w) -: -oiu-.o- -phthalazine-) - acetic. Acids- ;; , megluminated salt.
R a sv o p 3 - C 5 - t p u) t cme t i g l b i i t t - a e ol - 2 - and l m et t il) - 4 - o k s o t a l a and n -1 - i and i - acetic acid (419 mg) and meglumna (196 mg) in methanol (50 ml) are stirred at room temperature for 1 hour and then evaporate to dryness . The residue is thoroughly triturated with an efrom (25 ml), filtered and the collected solid portion is dried at the closet (610 mg, -. Mp, 157 ° C),
Example 21, 3 (5 Nrrmbenzotiz ozl-2-ylm etyl) -4- o k of ofal z i p-g - i - yl - acetic acid, methyl chlormine salt.
A solution of 3- (5-b rhombus with a thi-1 sol-2-yl methyl) -4-oxophthal in-i-ethyl acetate (430 mg.) P meg / min (196 - n in methanol: ( 50 ml) are stirred at room temperature g for 1 and then evaporated. The residue is; -: 23 ml are thoroughly triturated with e-lira and the solid product from lnl is rubbed (620 mg, mp, -140 CC),
Example 22 These. (2-seg. Nshstetil e nz ot ig. Z o l - 2 - i i. IM e il) - - - o with -N-ft lagshi- -lepatat
To an ice-cooled solution of ethyl- (5-thiomethylbine;;:; 1zol-2-nlm1- - type) -4-oxophthalicol-1 shane: - g y (1.06 g) in chloroform (O MJ to ( ha: -; - ice l m-Chloroperbenzoic acid Kisgo-y (0.50 g). The resulting solution is stirred at temperatures; O-CG for 1 h. KporoPopmzhg solution hfymyvagat 10% ppcr o bicarbonate sodium (3 x 20 ml) is organic, dried over magnesium sulphate and evaporated to dryness. The residue is washed with chromatographic silica gel and goglu Oj81 g compound
4H NMR {CDC1), 60 MG:;: i, (t, J 8 Hz, 3N), 2.65 (s,, 95 (s, 2H); 4, (q, T - 8 Hz, 2ij) I. 5 .75 (s, 2H); 7.4-8.3 (M, 7fi;.
PRI me R 2.3, Et: -1.n-3- (5-suk-: boilmethilbenzota and azol - 2 - ilm et il) - 4 - -oxo-3H-Cb-stasia- -yl acetate
A solution of ethyl- (-5-tkome gilbenzotnzzol-2-ylme: tyl) -4-oxo-3H-: lta; 1azin-1-ylacetate (1.06 g) and m-chloroperoxybenzoic acid (1, 3 rj in chloroform (5C ml) are peremeggzyayut at room temperature for I c. This solution is washed with 10% sodium bicarbonate solution (3x20 ml
j j; i: a.4H4ecKiu; zks sra.k i:. - steam up to :: iJj: y eini: siech lo-l ate h ;; h gp-ryly product (0.85: j,., GMP (CDCl, 5 (.i ,,): |, v (;,
31) /; ; J (s, 3; 0.1 d, o (s, 2iO f.,; H
(kj, J - 8: d, 21), B5 (s, :); n - 8.3 (m,,.
PRI me R 24, Etnl-3- (5-tri-I p Formion-2-0;; -methyl {-enotium -JOT and: G - - -oxo-ZN ft;: a and -1 -nlaceta1: (, - OS, AND- B. -li; К 5 -: Л1, Ег -: - -trnfluoromethin- 2-bepzothiazolpl. X -
BUT . 1 - (2 - BEPOTE; ZOLLL) TriLriXji.ripii ;;
15K;;; 2 bepzotiaroln: t a-
Nilchloride i, .j ..; ; - -) .lu: pi; th - thief g: ereme. : rlk1t:; n gomnatnoy .- ratu) e n Tr-K Hi f 1, I s.chuchein .: ENT 1 / F .i:; .-;.;. :,: G: and note -rgag iches.kg G-sks: :: i; i. ; :,; y;: p; Gzhst rlkt i pc mb; in a south: ;;, ln; / karpon gog-; 1 0 ml g and gtgm water (jO m;), m hyrid-: sutach (gad.: Shym :: d .-:, .-: m.chgnn n.: L. 1 | M 1 l o; : .- etttt -; - t /
:; - - (Z-Gria g Op: -: n: i-2-c:, - .о:.
;about. ; I; T): -yyy; co.p.
K ox: .i; -Tj f to another n; -. l.p.u. P --- glop. I - (z-trnshtormetil-.-Otp. H.: ;;; .- 1 etalo.aa Gs ;; l, -) j-Y--: 1 G. 4., 9--:; at :
Home | nr ;;;; il | 3,: ОПа -ij ;; 1 1; - bills y y ;: h; - .i o nylpiamm ;; Vol.,.:;, p1: :-) tJinp CM and: 4th st1 st layer -: city: l with hydrochloric acid (2 O UL). f -: v-ganpic dry extract. r aryl; .v and the residue of ttsu glno ras: mra; o - with r; -: - san until obtaining of coc.riici pulp
n-acetate (2.34 g) and -M: Cr:; ::: (0.53 g ,, 50% eu /. ;; gss dig: ip -: - mineral oil) in dimethylformal : -P5d (25 ml) was stirred at room temperature for 30 minutes under a nitrogen atmosphere. To the resulting solution, 1 - (5-trifluoromethl-2-bé: zothiazolyl) ethanol methylate (3., 2 g) was added, races: -29,
d to 4, 0 by adding I0% hydrochloric acid (5 ml), and extract with ethyl acetate (100 ml). The extract was washed with water (50 ml), dried over anhydrous magnesium sulphate and evaporated. The product is purified on a chromatographic split with a silica gel, eluting with ethyl acetate-chloroform (5/95% mixture). After evaporation of the eluate, 2.0 g of compound are obtained, m.p. Yu5-106 ° C.
Example 25. 3- (Benzothiazol-5-ylmethylbeneothiazolyl) -4-oxo-Phthalol ein-1-yl-acetic acid.
A.5-Bromomethylbenzothiazole was prepared according to the method of Example 10 starting from 5-methylbenzothiazole prepared according to. the way Crazz Chim Ital 95, 499 (1965)
The NMR spectrum of the product gives the following peaks from TMS (60 MHz, CDC1): 4.6 (s, 2H), 7.4 (dvd, 1H, J iO and 2 Hz) j 7.85 (d, 1H, J 10 Hz) -, 8.15 (d, J 2 Hz); 9.0 (s, 1H).
B. Ethyl-3- (5-methylbenzothiazolyl) -4-oxo-3H-phthalazin-1-ylacetate, obtained by the method of Example ID has the following spectrum.
NMR (60 MHz, CDCl1): 1.2 (t, J 8 Hz, 3N); 3.95 (s, 2H) - 4.2 (q / m
itel
.
7-C1
ropil
ropil
SOGE1
b.p.
5 o
Product
Famous
Known so pl. 189-190 ° C m.p. 250 ° C m.p. 224-225 ° C m.p.228-230 ° C m.p.23 23 -232 ° C m.p. 172-174 ° C
NMR (300 MHz, ASCS): 8.28 (cs 1H) 1, 7.63 (d, J 3 Hz, 2H), 1 4.12 (q, J 9); 3.92 (s, 2H); 3.04 (sep, J 9 Hz, 1H), 1, 25 (d ,, T 9 Hz, 6H) 1, 1.16 (t, J 6 Hz, GD) NMR (300 MHz, CMS): 8, 32 (d, l
9 Hz, 1H) ", 7.65 (dd, J 1
Hz
1H), 7.55 (s, 1H); 7.55 (s, 1H) 1, 4.15 (q, J 9 Hz, 2H); 3.96 (s, 2H); 3.06 (sep, J 9 Hz, IH); 1, 27 (d, J 9 Hz, 6H): isi8 (t, J 6 Hz, ЗН)
15
20
25
5124630
J 8 Hz, 2H); 5.6 (s, 2H); 7.2-8.2 - (m, 7H) j 9.0 (s, F).
C. The title compound is obtained by the method of Example IF, so pl. 203-204 ° C.
Example 26. Ztil-3- (5-Fluoro-benzothiazolyl-2-ylmethyl) -4-oxophthalzinyl methylate. Yuk mixtures of ethyl 4-oxo-ZN-Ftalazin
- α-acetate (2.34 g) in dimethyl formamide (15 ml) was added sodium methoxide (0.51 g). To the clear solution obtained by stirring the mixture for 5 minutes, was added a solution of 5-fluoro-2-chloromethylbenzothisol obtained by the method of Example 1C in dimethylformamide (5 ml). After stirring the resulting solution for 1 h, it was poured into ice-cold water (50 ml) and extracted with methylene chloride. After evaporation of the organic extract, a light orange solid is obtained, which crystallizes from ethanol to give the compound (3.84 g, m.p., 118-120 ° C).
A. The following is the data for intermediate known compounds (the first two), and the rest for intermediate compounds obtained by the method of example 1ZS.
Hz
155i24b5, 14, dmso-dg): 1J.O-.2.6 (unp II J, P, 4 (c,) i 8.2 - /, 9 IK, 2H4 J on o in, J 9 Hz, 2H, 4 , 98 (c 51 i I / i (t, I 9 IL, 3H) NMR f, p gftt, PMSO-dg): 13.0-12.6 (width I j),, 5 U, J - 9 Hz IH) 8.2 m 1H), 8.1 (c, 1), 4r, 0 (KB J - 1 u, 21); 4.10 (s, 2NG 1 15 C g J 9 Gg, 3N).
In table.0 we give the thunderbolt joints obtained with f
SfpT -CHZX I о v / 1
6H Ky
t-C1
6-OSN
AT(

-F 7-clN b-c1
- h F
L P P
C1
C1
C I
CI C I C1
yyyy peg dou: - (h ukap iy
t b 1
1 Р, t Г j
-, I), g, -)
and /, t. | -; at
S t, J - n g, i
1 f /
i f f;
T f r I l i
2 8Л (m, c) Mt CDCL, 90 ri /) 8.00 (- b) 8
i h
(1H (SONG. 9G t,}, 1 (dI L}
G ,, W) VfiP i CDC 3, 0 ru1
4.7C V, 2), /, 0- (L.D 10 7. (c, J -; I, i, T - Q Hz, 1 P
,, 90 ps Hi,, ts (t. H, 7.60 (s, h,
8 Hz, 1H)
78-80 14-115
YAG R (SOS e, 60 MI tr): d, l r, jr i 7.0-7.9 Cm, 3N 68-70 74-76

F (SOC, 60 MHz). h, U, H
6, f (d, 2Hf j 10 Hz), 7 i. , j - - 14 q)
4-C1, 7-C1
5-CH3
6-Ieopropil
H
H H
Ch.
134-135
Cl114-116
NMR (CDCl, 90 MHz): 7.85 (d,
J 9 Hz, 1H); 7.65 (d, J 3 Hz, IP); 7.40-Cdl, J 3 and 9 Hz, 1H) J 4.9 (s, 2H)} 3.00 (cen, J 6 Hz, IF), l, 35 (a, J 6 Hz, 6H )
NMR (CDC13, 60 H5 Hz): 2.0 (g. LC
J 8 Gp), 5.4 (KB, 1H, J S Hz) 1, 7.0-8.0 (m, 4H)
Obtained by the method of Can.J.Chem 43.2610 (1965)
C. The following intermediates are prepared according to previously known methods or according to the methods of a prize winner 13.
spruce

Product
Liquid, m / e 228,
about,
m.p. 134-135 С
D. 5- (2-Chlorophenyl) -2-chloromethyl- -1,2,4-oxadiazole,
but. 8-2-Chlorobenzoyl-chloroacetome-doxy. Chlorapetamidoxime (5 g) is dissolved in warm benzene (20 ml) and 2-chlorobenzoyl chloride (6.4 ml) is carefully added to it. The resulting mixture was heated at 40 ° C for 30 minutes, the excess benzene was removed. After cooling to room temperature, the mass is ground, thoroughly triturated with cold benzene and filtered to obtain the compound (1.6 g, mp 126-130 ° C)
Continuation of tsp
0
five
0
five
Q
five
b. 0-2-Ulorobenzonone-chloroapetamidoxime (1.4 g) is added to the CNSB under reflux of the diglyme (1C mp) and refluxing is continued for 1 0 m (After cooling, the reaction mixture is poured into water ( 20 ml), containing 50 ml of esyr. The ether layer is washed with water (ml), with a saturated aqueous solution of bicarbonate in UAH (2 M ml), the organic is dried and evaporated. oils.
And NMR (CDC13, 60 MHz): 4.7 (p.2H),
7.45 (y, 3F); 8.1 (m, 1H)
e, 2-Amino-3-hydroxypyridine 5.0 g / d of 30 ml of SO ml is heated at 125 ° C to obtain a solution. 2-chloro-1,1,1-triethoxy-ethane (9.9 g) is added to this p stand and the resulting mixture is kept for three hours. The resulting solution is cooled to a condenser temperature (and then decanted to remove H1- the black by-product residue. The obtained filtrate is diluted with water. (50 ml) and the precipitated yellow precipitate is recovered.
7-Y
Chl o rm e til o k sa zolo ,, 5-bj-pyridine 1.5 g). A small crossover is formed of izopopznola (so pl. 115-118 g).
2-Phenyl-5-chloromethyl- 1, 3,4-oxa-diaa aeol
2-Chloromethyl-5- -chlorobenzotioPhen Z-Chloromethyl-5- 2-chlorofesh) -, 2,4-oxadiazole
K-Methyl 2-chloro
m et sila
3-Methyl-4-6thrommethyl-1, 2,5-thiadia ol / 7 mm Hg.
G. Benzoate 4-fennthiazole 2-methanol (7.4 g) is dissolved in anhydrous tetrahydrofuran (50 ml). To this solution, p about b and b is the llyuminium g i g i t.kip.30-35 C /
i „-Trp-1 i about; Ske:;.:. 1.97.3 g) p N-chloros y. tsmim.chdl CHb,;
H (HG rehHLoris TO carbony -,; C: L /
heated to 40 ° C, and then b-luchnut UV lamella. The re-pack becomes exothermic, and then a precipitate forms before the reaction closes. OceBuni; 1 sous; P:--; the imide product is filtered off, and carbon tetrachloride is evaporated from the filtrate. The residual liquid is distilled to obtain pure 2-chloro.
b. A solution of 2-chloro-1,1-triethoxyet (5.9 g) and 2-amino-thio (benol (2.5
heated at 80 ° C for 15 minutes After cooling to room temperature, it is dissolved in methylene chloride (30 ml), the resulting solution is washed with 3N. HC1 (J 0 ml) and then water (20 ml). The organic part is evaporated and the residue is chromatographed on silica gel to give 2-hlmethylbenzothiazole (3; 35 g, 90% yield, mp, 34 ° C).
K. 2-Chloromethyl-5-bromobenzothiazole.
A mixture of the crude complex of 2-- -amino 4-bromothiophenol to tin-hydrochloride (7.6 g), 2-chloro-, 1,1-tri-ethoxyethane (58.7 g) and ethanol (400 ml is heated under gentle boiling under reflux for 30 minutes until solution is obtained. To the warm solution is added 3 N, CS (10 ml) and the precipitated solid is collected, washed with water and then dried to obtain the indicated compound (35; 5 g, m.p. 107 ° C).
L. a. 2-amino 4 triformstiltyphenol, hydrochloride.
4-Chloro-3-nitrobox rifluoride
(100 g) is dissolved in ethanol (400 ml. To this is added in portions the solution obtained by first adding sodium sulphide hydrate f80 g to hot ethanol (200 ml) and then sulfur / 9.6 g. After exothermic heat the reaction is quenched, the reaction mixture is boiled under reflux for an additional 30 minutes, and then cooled to room temperature. The precipitated yellow solid is collected, washed with cold ethanol, and the aroma is dried until 4,4-ditrifluoromethyl-2, 2-nitrodiphenyl disulfide (63.0 g, mp 152-154 ° C). A mixture of this compound (62 g), a metallic tin (20 ml, 132.0 g), ethanol (500 ml) and concentrated HCl (200 ml) are carefully boiled under reflux at 80 ° C until solution is obtained. The reaction mixture is then kept at 70 ° C for 30 the warm solution is filtered, the filtrate is concentrated under reduced pressure to a viscous liquid, 6N HC1 is added to it and the precipitated white solid is filtered off, to give
0
five
Q
five
0
five
five
0
five
0
49.0 g of the title compound; mp. 208-209 ° C.
B. 2-Chloromethyl-5-trifluoromethylbenzotnazole.
To a solution of 2-amino-4-triFluoromethyl-thiophenyl hydrochloride (30.0 g) in ethanol (1 25 ml) was added 2-chloro-1,1, -triethoxyethane (31.0 g). The resulting mixture is heated for 1 h at 60PS. The resulting solution is concentrated to remove excess ethanol, and the resulting material is extracted with ether (500 ml). The organic extract is washed successively with 10% HC (20 ml), water (100 ml), I0% sodium bicarbonate solution and water (P 00 ml), and then vnv-g to obtain an amber oil, which crystallizes at nii at room temperature (28.9 g, mp, 52 C).
M. 2-Chloromethyl-5,7-dichlorobenzoxazole.
To a solution of 2,4-dichloro-6-n-trofenol (10.0 g) in water (450 ml) that absorbs sodium bicarbonate (4.8 g), add a sodium dithionate to the amount of PGR. sufficient to source; the dark solution became colorless. The hot reaction mixture is opHl-Lt-Lt, and the resulting filtrate is cooled to room temperature and the crystallized product is collected - 2-α-amino-i, 6-dichlorophenl (1.6 i), which is then dissolved in ethanol (5 ml ) and 2-chloro-1, 1, I-triethoxy-ethane (1.9 g) is added, the resulting solution is heated on the steam bath for 1.5 hours. After cooling to room temperature, 5 ml of cold 1 water is added. The precipitate precipitated is collected and then dried in air until the indicated compound 0.12 - g., Pl. 52-53sG).
N. 2-Chloromethyl-5-bromobenzoxazole.
2-Amins-4-5-thromophenol (1.6 g) was dissolved in ethanol (5 ml) and 1.9 g of 2-chloro-1, 1, 1-trn-toxnesch were added on to. The resulting solution was heated on the steam bath for 1.5 hours. After cooling the reaction mixture to room temperature, add 5 ml of cold; water. A solid precipitate is collected with ui: a t in the air, resulting in a product (1.12 g, mp,).
0. According to a method similar to Example I (b) 3, 2,2-chloromethyl-5J91551246 is obtained.
chlorobenzoxazole with t, gsh. (. Ig; 2-amino-4-chlorophenol, for example, ethanol: chloroform as a solvent: instead of methane chloride; Anaogichno, 2-chloromethyl — 5-methylthiobenzothiazole with mp, 65-66 ° С and 2- Chloriethyl-5-cbtorbenzothiazole with thiyl, 73 ° C, is derived from 2-amio 4 - methyl thiosbenol hydrochloride salt and 2 ™ amine-4-methylthnoenol hydrochloride, respectively, but ethanol is not a solvent.
R. 5- Ulormethyl-2-phenyl 1 53,4-ok-sadiazole.
A mixture of 2-chloro ™, 1,1-triztoksiota-on (4.8 g), benzoshtgzdrazina (3.0 g) and ethanol (30 ml) is refluxed for 2 hours and the resulting solution is allowed to cool to room temperature. To the precipitated white crystalline solid is added 10 ml of zoda, which contains a few drops of 0% nNHCl. The resulting mixture is stirred for 10 minutes, then filtered and the solid product is collected, the mother liquor is evaporated to dryness: the broth is thoroughly triturated with to, until it is hot (silt until a second portion of white solid is obtained. About, the portions together yield 3.8 g (89 %) product ..
from the floor
-e
but de
Jq to ne ne na (bai
I ne from fe
at
corner 1)
ba
not l
25 wasps
(one
We are sp (I my pr with
Example 27 2 - Chloromethyl-5-bromobenzothiazole „
A mixture of the crude complex of 2-amio-4-bromo-thienyl phenyl hydrochloride (71.6 g), 2-chloro-1,1, -triztoxyethane / 58.7 g) and ethanol (400 ml are heated to reflux for 30 min. to obtain a solution, 3N HCl (10 ml) is added to the warm solution, and a solid precipitate formed is separated, washed with water and dried to give the compound (35.5 g, mp, 107 ° C)
Example 28. 2-Chloromethyl-oxazole 4,5-blpyridine,
L.о /
2-Amino-3-hydroxypyridine, 0 rl and diglyme (30 ml) are heated at 1. 2 ° C to form a solution. 2-chloro-1, -triethoxy ethane (9.9 g) is added to the solution and the mixture is kept at 125 C for 1 hour. The solution is cooled to room temperature and then decanted to remove black residue.
semi-product. The filter is diluted
Water (5-0 ml) and the resulting yellow precipitate
separated (1.5 g). A small part of the recrystallized o from the out of the zones of the ropat-, la (t.p.115-118 ° C).
Example 29, 2-Chloromethyl-5, V-dichlorobenzoxazole.
To a solution of 2, 4 - dnhlor-b; Wg of lenol (10.0 g) in water (450 ml) containing sodium bicarbonate (45 V g)
Q add sodium dithionate to a sufficient amount before changing color; of the initial dark solution, the heated reagent 5 chickpeas the mixture is filtered (the filtrate is cooled to room temperature, the product of the stall is separated 1.6 g by 2 ami;
The whole of the obtained i-product rg gts p; is in ethanol (5 ml) and 2-uloyl is added
d) 1 5 1-triethoxyethane ()., 9 g),; Oh, p. The custom raspor heats up on iTap. G:
bath for
h, 1 os;:; or before the com-secret temperature temp; -.- lpb ;; poured ashes (5 UL), T: -r-r:;: sediment section and then n-c, ml, n ;; In the spirit, getting the named is connected:. (1.12 g, mp, 52-53 ° C),
Pharma, eutically acceptable wasps: salt - trisosdiaen soy;: m: -sr- (I), where K is oxngr: -.-..--:, can be obtained from the La rmlcentic ;; receiving cations-; c6i, r-i :: r; -; and r :: cv- sobamp. So, atg- with: wolns :: ::; o get, arr, -1bach soy; 1) -: nenie; boi
Mvnbi (I) NATIVE races. Vogue1;: elrr): - o
pharmaceutically pg-imle south kp ;;. : n ;; After evaporation, the resulting i.r: r: y-ha xy is obtained, preferably at r; s ..-. m .- :: -. v pressure. In another version 5 par-; t: s ..- lower alkyl alcohol yr ;; dLnn of the formula (I) can be mixed with the lggycid of the target material and the UI / larnp.
for this we sang in the key lk-t,. however:; e are limited to them, such: ;;; - io ::. alkali metal like potassium: -. ammonium or water soluble .. ::::; addition of amine s -cate ctc -: -: o tilglucamine (meglumine), lower alkanolammonium and other wasps. salts with organic amines, which are pharmaceutically acceptable, and alkaline earth metal cations such as calcium or magnesium.
Pharmaceutically acceptable acid addition salts of the compounds of Formula (I) are prepared by a conventional method, treating Ft or suspension
free base (I) is about one chemical equivalent of a pharmaceutically acceptable acid. In isolating these, conventional concentration and recrystallization techniques are used. Examples of suitable acid is acetic, lactic, succinic, maleic, tartaric, citric, gluconic, ascorbic, benzoic, cinnamic, fumaric va, sulfuric, phosphoric, hydrochloric, bro mistovodorodnpch, iodistovodorotsna, sulFaminovr, eupshonov example metaneulfokislota, benzosul - phonic acid and genus hydric acid. It is preferable to use phosphoric acid as acid.
The novel compounds of Formula I and their pharmaceutically acceptable salts are aldose reductase enzyme inhibitors.
The effect of such aldose reductase inhibitors is to inhibit
of the peptide of aldo-25 in perluch.ch- O.ge- regulation, such as up to г ° е с с т в вд НА (NADGE with dg dose; p 1 μg of the quality of the center
polyols, gzigu k k seraigol and galactitol, in humans and animals. Thus, the accumulation of galactitol in the lenses of galactosemic patients and sortes in lenses, peripheral neuronal tissues and kidneys of various diabetic patients is prevented or reduced. Accordingly, such compounds are of therapeutic value as inhibitors of al-dosage reductase to control various chronic complications of diabetic origin, including natural ones, as specialists know that the presence of polyolea in
the lens of the eye leads to the formation of cataracts and is accompanied by a decrease in the transparency of the lens. The test method.
Enzyme preparation.
Aldosoreductase (AP) is partially purified from human placenta using the modified Haiman and Kinoshita method described for rat lens. Freshly received placentas are homogenized in 3 volumes of a 0.1 molar potassium buffer solution with a pH of 7.0, which contains 5 mmol of 2-mercaptoethanol, and
0
five
0
; from in a centrifuge for 20 minutes at i JC and an acceleration of 33,000 xg (9.8m 2 / s). The combined supernatants from the previous stages are fractionated with 30-75% ammonium sulfate. The resulting tablets are resuspended together in a minimum volume of buffer and dialyzed overnight. The dialysis product C4j.inu-.pT chromate is rafted on a DEAE-cellulose column, with the aldose reduction being glued to r, pv, a linear chlorine gradient: ui kg. Grig SO-1 corner ..- i-}. PI.CHOR with erakgtch, solcherl; not alg; nr UVK g hr y, are combined with gl kkot; r solutions of hrsN ° h of the replaced state, E ha H NRO ::; to the prog: waste, enriched with more than 30 p z of the RKGIRNOSTI of aldo-p-reduct-z1.
Spent with nne: -, -mm. gi Ald z-relurstazu use tyk11 gnd bichromate HK eskou clinical dna-o means
5 mash
4ii
0
five
d 5
, „
5 ° С
(NADGE) at 2-: ° С Р for 10 - at a wavelength of nm. Dose unit; rdz ktaz; is defined as 1 µg ol RALHP, OXIDIZED at the time of min with dl-glyceraldegnd as substrate. The test subjects are evaluated at various hon-centers. The results are given as a percentage of the inhibitor test rate n: oxide: - 5 NLLHP. Condition gsg tacht h.
ALTOZORSDU} 1G ZU riC rlTI- BaiC i 3
0.25 ml of buffer ptvtorg (5C. / L) PhosFgta potassium, t, 1, which is solsr. 400 mon :: l of ammonium sulfate; 0.067 mmol / l CHLDP1 and 0.5 mmog / l cP-h ceraldeg nda. Add two times the amount of enzyme needed to ensure the oxidation rate of NADH-i. equal to 4 min. :: mon
It is given: - :: c- pspyplng. The suggestion below.
1C 50 SMOLKG)
2, 7, 79 x 10 1, OOU 2513xiO S, 2,
The compound of formula I1,2J 10 (P, - OH, P, g - quinazolin-2-yl, ". - CL). Compound known 1,
-at
g
From the above data it can be seen that the proposed compounds have a higher activity than the lime compound.
The proposed compounds in the tested doses showed no signs of toxicity, they can be attributed to the low toxic toxicity.

权利要求:
Claims (2)
[1]
1. A method for producing oxophthalisin acetic acids of general Formula I
D QHiSORi
0 CHZR2
Rs
0
S
where I R.
R- 0
five
0
five
0
R HR4R
a covalent bond or grg hydroxy group of ity CC, -C alkoxy;
a hetero-cyclic pythic ring containing a nitrogen atom and one of a kind, or sulfur, or dvg. m and one oxygen atom of sulfur, with the indicated j - zo replaced by one C, - alkyl or Phenyl, M.IH is condensed from the bench, and the specified th-th or benzogroup is unsubstitutedly replaced by one saviecTHTt flax, such as Tribchor etyl (C „-Sf) -alkyl,) -agk Kgi, (C, -Sf) -alkyliig. (C (-C) -alkylsul, () -alkylsul fonip it one or two - dvec guitar, such as fluorine, chlorine
OR bromine, KHINOLIN, KHINOKSg1lin, oxazole, thiazole, chlorobenzothiophene or 7-chloroimidtzol, condensed g PP
Ridin,
the same or distinguished P
every dominion - ENT, ytgbrom, triFgor etil, ()
alkyl, () -alkoxy or
nitroJ
hydrogen or methyl
or their pharmaceutically acceptable additive basic salts, HR R. is a hydroxy group, or additive acid salts, where (C.-C,) is an alkoxy group substituted by N-morFolino or di-SS Cd) is alkylamino, o tl and h and s and with the fact that, the compound of the general formula I
n CHzGORi
3 sr-sx N
where R, E and If have the indicated meanings,
subjected to interaction with the compound of General Formula III
L-CH-Z-R2 R5
R
where L is chlorine or bromine;
and T is as defined.
with the release of the desired product, or, if P ,, - (C, -C) -alkoxy, by carrying out hydrolysis prior to the formation of the corresponding compounds, where R ,, is hydroxy and, if desired, is transformed into pharmaceutically acceptable additive base salts by interaction with pharmaceutically acceptable cation and, if necessary, alkylation
sodium salts of compounds of the general Formula, where hydroxy.
[2]
2. The method according to p. Characterized in that use the compound of General Formula III, L-CH-Z R7 Rs
15
0
five
Where
chlorine;
R5R 1
L 2, covalent bond, hydrogen,
oxazole or thiazole, condensed with Y, where Y together with C2 to which it is attached, forms Phenyl or pyridyl,
compound of Formula IV obtained by reaction
X-NH2 Y I
xs-hn
where X is oxygen or sulfur;
Y has the indicated values with tri- (C, -C4) -alkoxy C-CH4Cl.

类似技术:

公开号 | 公开日 | 专利标题

SU1551246A3|1990-03-15|Method of producing phthalizineacetic acids or their pharmaceutically acceptable additive salts

EP0091241B1|1988-12-28|Condensed pyrrolinone derivatives, and their production

AU668694B2|1996-05-16|Saccharin derivative proteolytic enzyme inhibitors

JP5306373B2|2013-10-02|Amyloid β modulator

RU2100357C1|1997-12-27|Heteroarylamines or their pharmaceutically acceptable salts and pharmaceutical composition based on thereof

HU213113B|1997-02-28|Process for producing 2-aminobenzoxazole and 2-amino-benzothiazole derivatives and pharmaceutical compositions containing them

EP0243018B1|1990-10-24|Thiolactam-n-acetic acid derivatives, their production and use

GB2177089A|1987-01-14|Thiazolidinecarboxylic acid derivatives

AU640300B2|1993-08-19|Pharmacologically active substituted oxybenzamides

US4717725A|1988-01-05|Ophthalmic wound healing with aldose reductase inhibitors

US4755509A|1988-07-05|Heterocyclic aldose reductase inhibitors and methods of using them

FI79319B|1989-08-31|FOERFARANDE FOER FRAMSTAELLNING AV NYA TERAPEUTISKT ANVAENDBARA TRICYKLISKA OXINDOLKARBOXAMIDDERIVAT.

CA2116117A1|1993-03-04|Benzisoxazole compound and use thereof

CA2010217C|2002-01-01|Aralkylamine compounds

EP0644191A1|1995-03-22|Pyridine compound and medicinal use thereof

CS250681B2|1987-05-14|Method of 1-alkylsubstituted 1,4-dihydropyridinlactones production

CA1299178C|1992-04-21|Heterocyclic oxophtalazinyl acetic acids

US6797717B2|2004-09-28|Anilide compounds and drugs containing the same

US5453518A|1995-09-26|Flavone derivatives

Rakowitz et al.2005|Synthesis of novel benzoic acid derivatives with benzothiazolyl subunit and evaluation as aldose reductase inhibitors

IJEOMAH et al.2021|SYNTHESIS, CHARACTERISATION AND ANTIBACTERIAL ACTIVITY OF 2-| AMINO PYRIDINE.

DD232045A5|1986-01-15|PROCESS FOR PREPARATION OF PRECIPITATES DEEP-REDUCING OXICAME

FI77869B|1989-01-31|FOERFARANDE FOER FRAMSTAELLNING AV SUBSTITUERADE KARBOXITIAZOLO / 3,2-A / PYRIMIDINDERIVAT MED EN ANTIALLERGISK VERKAN.

US4507477A|1985-03-26|Process for tetrazolyl-pyrimidinone derivatives

AU607866B2|1991-03-14|LO/CO inhibiting benzoxazolones

同族专利:

公开号 | 公开日

ES2032749T3|1993-03-01|

EP0222576A3|1988-03-23|

EG18144A|1992-08-30|

DK172010B1|1997-09-15|

KR890002758B1|1989-07-27|

DK529886D0|1986-11-06|

PT83684B|1989-06-30|

PT83684A|1986-12-01|

FI864512A|1987-05-08|

NO168303B|1991-10-28|

AU574589B2|1988-07-07|

IL80475A|1993-01-31|

YU45027B|1991-06-30|

NO864425D0|1986-11-06|

NO864425L|1987-05-08|

CN1009831B|1990-10-03|

GR3004099T3|1993-03-31|

FI87355C|1992-12-28|

NO168303C|1992-02-05|

FI864512A0|1986-11-06|

FI87355B|1992-09-15|

DK529886A|1987-05-08|

KR870004981A|1987-06-02|

EP0222576B1|1992-03-18|

DE3684410D1|1992-04-23|

IE862923L|1987-05-07|

NZ218192A|1989-08-29|

PL262266A1|1987-11-30|

YU189086A|1988-06-30|

AU6485886A|1987-06-11|

PL151024B1|1990-07-31|

CN86108308A|1987-07-15|

IE59315B1|1994-02-09|

EP0222576A2|1987-05-20|

引用文献:

公开号 | 申请日 | 公开日 | 申请人 | 专利标题

IE47592B1|1977-12-29|1984-05-02|Ici Ltd|Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture|US4939140A|1985-11-07|1990-07-03|Pfizer Inc.|Heterocyclic oxophthalazinyl acetic acids|

US4868301A|1987-06-09|1989-09-19|Pfizer Inc.|Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains|

IL87709A|1987-09-16|1992-11-15|Pfizer|Process for preparing haloalkyl thiazoles and some such novel haloalkyl thiazoles|

EP0322153A3|1987-12-21|1990-08-16|Pfizer Inc.|Heterocyclic oxophtalazinyl acetic acids|

WO1989006651A1|1988-01-19|1989-07-27|Pfizer Inc.|1h-indazole-3-acetic acids as aldose reductase inhibitors|

US4940791A|1988-02-29|1990-07-10|Pfizer Inc.|Process for the production of phthalazineacetic acid ester derivatives and a novel hydrazine containing intermediate|

US4904782A|1988-02-29|1990-02-27|Pfizer Inc.|Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate|

US4954629A|1989-05-11|1990-09-04|Pfizer Inc.|Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof|

US4996204A|1989-05-11|1991-02-26|Pfizer Inc.|Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors|

FR2647676A1|1989-06-05|1990-12-07|Union Pharma Scient Appl|New pyridazinone derivatives, processes for preparing them and medicaments containing them which are useful, in particular, as aldose reductase inhibitors|

US5304557A|1989-12-15|1994-04-19|Pfizer Inc.|Substituted oxoophthalazinyl acetic acids and analogs thereof|

US5039672A|1990-04-05|1991-08-13|Pfizer Inc.|Heterocyclic compounds as aldose reductase inhibitors|

US5037831A|1990-05-21|1991-08-06|American Home Products Corporation|Spiro-isoquinoline-pyrrolidines and analogs thereof useful as aldose reductase inhibitors|

US5064830A|1990-08-02|1991-11-12|Pfizer Inc.|Lowering of blood uric acid levels|

WO1992003432A1|1990-08-28|1992-03-05|Pfizer Inc.|3--4-oxo-3h-phythalazin-1-ylacetic acid monohydrate|

DK0720621T3|1992-01-14|2001-08-06|Diatide Inc|Radiolabeled somatostation-derived peptides for imaging and therapeutic applications|

US5700819A|1994-11-29|1997-12-23|Grelan Pharmaceutical Co., Ltd.|2-substituted benzothiazole derivatives and prophylactic and therapeutic agents for the treatment of diabetic complications|

IL124236A|1997-05-05|2003-01-12|Pfizer|Pharmaceutical composition for treating or reversing diabetic cardiomyopathy comprising aldose reductase inhibitor|

DE69918278T2|1998-03-31|2005-07-14|The Institutes for Pharmaceutical Discovery, Inc., Branford|SUBSTITUTED INDOLALCANIC ACID|

US6570013B2|2000-02-16|2003-05-27|Pfizer Inc|Salts of zopolrestat|

WO2002098429A1|2001-06-07|2002-12-12|Pfizer Products Inc.|Ethanolamine, diethanolamine or triethanolamine salt of zopolrestat|

DE10225750A1|2002-06-10|2003-12-18|Degussa|Process for the preparation of 2-chloro-1,1,1-trialkoxyethane|

CN101058558B|2007-05-28|2013-04-10|沈阳药科大学|4-Oxy-1-quinoline carboxylic acids compound and composition with aldose reductase inhibition activity and preparation method thereof|

ES2769950T3|2010-07-16|2020-06-29|Univ Columbia|Aldose Reductase Inhibitors and Uses thereof|

US8916563B2|2010-07-16|2014-12-23|The Trustees Of Columbia University In The City Of New York|Aldose reductase inhibitors and uses thereof|

SI3352754T1|2016-06-21|2021-03-31|The Trustees Of Columbia University In The City Of New York|Aldose reductase inhibitors and methods of use thereof|

法律状态:
2007-09-20| REG| Reference to a code of a succession state|Ref country code: RU Ref legal event code: MM4A Effective date: 20041107 |

优先权:

申请号 | 申请日 | 专利标题

US79603985A| true| 1985-11-07|1985-11-07|

US06/796,359|US4723010A|1985-11-07|1985-11-07|Process for preparing chloromethyl thiazoles or oxazoles, and intermediates for use therein|

[返回顶部]